February 2, 2021 11:29 AM EST

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6

Jason Mast

Editor

Amber Tong

James Sabry and Aviv Regev at Roche and Genentech have been racking up early stage partnerships, tying up with early stage biotechs developing everything from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6

Jason Mast

Editor

Amber Tong

Sign up to read this article for free.

Patient dies in Neurogene's Rett syndrome study

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

RFK Jr. and Elon Musk want to ban pharma ads. They wouldn't be the first to try

Are programs with compounded GLP-1s safe for your population?

James Sabry adds an­oth­er weapon to Roche-Genen­tech ar­se­nal; Dai­ichi Sankyo adds ADC #6

Editor

Sign up to read this article for free.

James Sabry adds another weapon to Roche-Genentech arsenal; Daiichi Sankyo adds ADC #6